Survodutide
- Generic Name
- Survodutide
A Study to Test How Different Doses of BI 456906 Are Tolerated in Japanese Men With a Body Mass Index (BMI) Between 23 and 40 kg/m2
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2021-01-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 37
- Registration Number
- NCT04384081
- Locations
- 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan
A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2019-11-06
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 413
- Registration Number
- NCT04153929
- Locations
- 🇺🇸
Javara Research, Sugar Land, Texas, United States
🇺🇸San Marcus Research Clinic, Inc., Miami, Florida, United States
🇬🇧Burbage Surgery, Burbage, Hinkley, United Kingdom
A Study to Test Different Doses of BI 456906 in Patients With Obesity
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2021-03-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 131
- Registration Number
- NCT03591718
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
🇩🇪Profil Mainz GmbH & Co. KG, Mainz, Germany
Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 456906 in Healthy Male Volunteers
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2018-07-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT03175211
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath